CARNA BIOSCIENCES

News Release

October 23, 2023
Carna Biosciences, Inc.

Carna Announces International Nonproprietary Names Selection for AS-0871 and AS-0141

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announced that it has received approval of the International Nonproprietary Names (INN) for the company's two investigational drugs AS-0871 and AS-0141 from the World Health Organization (WHO) as below.

Code name	International Nonproprietary Name (INN)
AS-0871	sofnobrutinib
AS-0141	monzosertib

INN are assigned by the INN Expert Committee of the WHO to pharmaceutical substances to ensure recognition by a unique name. Going forward, Carna will use the INN for those two investigational drugs AS-0871 and AS-0141 in upcoming publications and public statements.

About AS-0871 (INN: sofnobrutinib)

AS-0871 is an investigational small molecule drug designed to bind non-covalently to Bruton's tyrosine kinase (BTK) with high selectivity, currently in development for inflammatory and immune disorders. In in vitro experiments, AS-0871 strongly inhibited B cell and basophil activation and suppressed production of inflammatory cytokines such as TNF-α, IL-17, MCP-1 and IL-6 in human blood. Oral administration of AS0871 demonstrated the excellent therapeutic effects in a mouse model of collagen-induced arthritis. In addition, AS-0871 prevented IgE-mediated skin inflammation in mice and rats.

AS-0871 is a highly selective and non-covalent BTK inhibitor discovered by Carna, being developed for the treatment of inflammatory and immune disorders. Phase 1 study of AS-0871 consisting of single ascending dose (SAD) study and multiple ascending (MAD) study was conducted in the Netherlands in healthy volunteers and dosing was completed in April 2023.

About AS-0141 (INN: monzosertib)

AS-0141 is a potent, selective, orally bioavailable small molecule inhibitor of CDC7 kinase, originally discovered by Carna. AS-0141 exhibited a potent anti-proliferative activity against various cancer cell lines including solid and blood cancers with minimal effects against normal cells. In several human tumor xenograft models, oral administration of AS-0141 demonstrated strong anti-tumor efficacy. AS-0141 is currently being evaluated in an open-label Phase I study in patients with unresectable advanced, recurrent, or metastatic solid tumors. This study consists of two parts: the dose escalation part that aims to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of AS-0141 and the expansion cohort aimed at ensuring the appropriateness of PR2D and evaluating the preliminary anti-tumor effect.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/